Get the Stockscreener App
4.085
12.53%
-0.585
After Hours:
4.10
0.015
+0.37%
X 4 Pharmaceuticals Inc stock is traded at $4.085, with a volume of 807.02K.
It is down -12.53% in the last 24 hours and down -0.61% over the past month.
X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
See More
Previous Close:
$4.67
Open:
$4.64
24h Volume:
807.02K
Relative Volume:
1.39
Market Cap:
$385.30M
Revenue:
$9.01M
Net Income/Loss:
$-99.72M
P/E Ratio:
-0.9002
EPS:
-4.5381
Net Cash Flow:
$-92.85M
1W Performance:
-0.12%
1M Performance:
-0.61%
6M Performance:
+2.12%
1Y Performance:
+119.62%
1-Day Range:
$4.06
$4.70
1-Week Range:
$3.92
$4.70
52-Week Range:
$1.35
$4.83
X 4 Pharmaceuticals Inc Stock (XFOR) Company Profile
Name
X 4 Pharmaceuticals Inc
Sector
Industry
Phone
857-529-8300
Address
61 NORTH BEACON STREET, BOSTON, MA
Compare XFOR vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XFOR
X 4 Pharmaceuticals Inc
|
4.085 | 440.47M | 9.01M | -99.72M | -92.85M | -4.5381 |
VRTX
Vertex Pharmaceuticals Inc
|
498.01 | 126.07B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
624.72 | 65.37B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
909.50 | 57.70B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.67 | 40.19B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
187.51 | 39.82B | 742.00K | -1.37B | -1.07B | -7.0731 |
X 4 Pharmaceuticals Inc Stock (XFOR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-09-26 | Initiated | Guggenheim | Buy |
| Dec-05-25 | Resumed | Stifel | Buy |
| Dec-12-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Aug-30-23 | Resumed | B. Riley Securities | Buy |
| Dec-22-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-12-22 | Initiated | Piper Sandler | Overweight |
| Dec-23-19 | Initiated | Oppenheimer | Outperform |
| Dec-18-19 | Initiated | ROTH Capital | Buy |
| Dec-09-19 | Upgrade | Citigroup | Neutral → Buy |
| Dec-05-19 | Initiated | B. Riley FBR | Buy |
| Jun-07-19 | Initiated | Stifel | Buy |
| Jun-05-19 | Initiated | Cowen | Outperform |
View All
X 4 Pharmaceuticals Inc Stock (XFOR) Latest News
Form 4 Shuttle Pharmaceuticals Inc For: 1 July By Investing.com - Investing.com Canada
Form 4 X4 Pharmaceuticals Inc For: 1 July By Investing.com - Investing.com Canada
X4 Pharmaceuticals CFO David Kirske sells $36,428 in common stock By Investing.com - Investing.com Canada
X4 Pharmaceuticals (XFOR) CFO sells 8,543 shares to cover RSU tax - Stock Titan
Director Kelly Gold granted 110,000 X4 Pharmaceuticals (XFOR) stock options at $4.085 - Stock Titan
X4 Pharmaceuticals (XFOR) director Gold Kelly files initial Form 3 ownership - Stock Titan
Kelly Gold joins X4 Pharmaceuticals (Nasdaq: XFOR) board and Audit Committee - Stock Titan
X4 Pharmaceuticals Announces Appointment of Kelly Gold as an Independent Director and Member of the Audit Committee, Effective July 1, 2026 - marketscreener.com
Form 4 Adial Pharmaceuticals Inc For: 1 July By Investing.com - Investing.com Canada
60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue - The Manila Times
X4 Pharmaceuticals appoints Kelly Gold to board of directors By Investing.com - Investing.com Canada
X4 Pharmaceuticals Appoints Kelly Gold, Experienced Chief Financial Officer, to its Board of Directors - marketscreener.com
X4 Pharmaceuticals adds CAMP4 CFO Kelly Gold to its board - Stock Titan
Form 4 Ionis Pharmaceuticals Inc For: 30 June By Investing.com - Investing.com Canada
Form 4 Processa Pharmaceuticals Inc For: 30 June By Investing.com - Investing.com Canada
Form 4 Eton Pharmaceuticals Inc For: 30 June By Investing.com - Investing.com Nigeria
Form 4 Vertex Pharmaceuticals Inc For: 30 June By Investing.com - Investing.com Canada
Form 4 Tarsus Pharmaceuticals Inc For: 29 June By Investing.com - Investing.com South Africa
Form 4 ACADIA Pharmaceuticals Inc For: 29 June By Investing.com - Investing.com South Africa
Cadrenal Therapeutics (NASDAQ: CVKD) names interim CFO and realigns board classes - Stock Titan
Universe Pharmaceuticals (NASDAQ:UPC) pop puts $10.75M patent deal and float in focus - TechStock²
6,000 vTv Therapeutics (VTVT) options granted to director tied to Baker funds - Stock Titan
Tarsus Pharmaceuticals (TARS) director receives RSU and stock option grants - Stock Titan
Following Satri Cel Approval Is CARsgen Therapeutics Holdings (SEHK:2171) Fully Priced? - simplywall.st
Is Alnylam Pharmaceuticals (ALNY) Undervalued Following Its Expanded Komodo Health AI Partnership? - simplywall.st
X4 Pharmaceuticals, Inc.(NasdaqCM: XFOR) added to Russell 2000 Index - marketscreener.com
Is HRMY Stock Worth Buying With Neutral Signals and Cheap Valuation? - TradingView
Is SYRE Stock a Buy Now or a Wait-and-See Biotech Story Today - TradingView
X4 Pharmaceuticals, Inc.(NasdaqCM: XFOR) added to Russell 2000 Value Benchmark - marketscreener.com
Nephrotic Syndrome Market Set for Robust Growth During the Forecast Period (2026-2036), Driven by Emerging Therapies and Expanding Research | DelveInsight - PR Newswire
Form DEF 14C Curanex Pharmaceuticals Inc For: 29 June By Investing.com - Investing.com Canada
X4 Pharmaceuticals, Inc.(NasdaqCM:XFOR) added to Russell Microcap Value Benchmark Index - marketscreener.com
Nuvation Bio Announces Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated in the United Kingdom - Investing News Network
Xilio Therapeutics taps biotech veteran Ben Harshbarger as legal chief - Stock Titan
BioCryst (NASDAQ: BCRX) lowers 2026 expenses and closes Birmingham R&D hub - Stock Titan
Talawar Therapeutics and JATT II Acquisition Corp. Announce Definitive Business Combination Agreement to Create Publicly Listed Biotechnology Company Developing Potentially Best-in-Class Bispecifics for I&I Diseases - PR Newswire
5 Biotech Stocks That Skyrocketed 105% To 235% — TWST, INDV, MIRM & More - RTTNews
X4 Pharmaceuticals, Inc.(NasdaqCM: XFOR) added to Russell Microcap Index - marketscreener.com
Is Spyre Therapeutics (SYRE) Fully Valued After Russell Index Removal And A $500 Million Offering? - simplywall.st
Pfizer’s CFO Just Left and a Key Drug Trial Missed. Here’s What That Means for PFE Stock in 2026 - TIKR.com
DAYBU® (trofinetide) Recommended for Approval in the European Union by CHMP - BioSpace
BridgeBio's achondroplasia drug posts NEJM Phase 3 data - Stock Titan
XFOR Forecast — Price Target — Prediction for 2027 - TradingView
Form 4 ARS Pharmaceuticals Inc For: 26 June By Investing.com - Investing.com Nigeria
Cadrenal Therapeutics (CVKD) CEO Quang Pham sells 11,156 shares under 10b5-1 plan - Stock Titan
Form 4 Ionis Pharmaceuticals Inc For: 26 June By Investing.com - Investing.com Nigeria
BVF group sells 1,630,658 Kymera (KYMR) shares in joint Form 4 - Stock Titan
Form 144 IONIS PHARMACEUTICALS INC For: 26 June By Investing.com - Investing.com Canada
ARS Pharmaceuticals (NASDAQ: SPRY) grants 30,000 options to RA Capital-linked director - Stock Titan
Director Rajeev Dadoo granted 30,000 ARS Pharmaceuticals (SPRY) stock options - Stock Titan
ARS Pharmaceuticals (SPRY) director Laura Shawver receives 30,000 stock options award - Stock Titan
X 4 Pharmaceuticals Inc Stock (XFOR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.52%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):